NCT06183645 Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.
| NCT ID | NCT06183645 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Liege |
| Condition | Chronic Inflammatory Demyelinating Polyneuropathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-08-28 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2023-08-28 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis. The investigators plan to include a group of approximately 40 patients with CIDP. The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with CIDP or possible CIDP based on 2021 EAN/PNS criteria2. * Treated with IVIg (≤1g/kg/3-8week) * Clinically Stable disease for 3 months (according to treating physician opinion). * No treatment withdrawal failure within 1 year * Age over 18 years Exclusion Criteria: * Significant cognitive or communication disorders * Surgery or serious traumatic injury ≤ 6 months * Non ambulant patient * Current participation to a therapeutic trial * Anti-myeline antibodies (anti-MAG) positive or nodo-paranodopathy * Other autoimmune disease that requires Corticosteroids, IVIg, Plasma Exchange treatment * Pregnancy or breastfeeding * Any other condition that, according to the investigator, could significantly interfere with patient evaluation or safety.
Contact & Investigator
Margaux Poleur, Dr
PRINCIPAL INVESTIGATOR
CHR Citadelle
Frequently Asked Questions
Who can join the NCT06183645 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Chronic Inflammatory Demyelinating Polyneuropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06183645 currently recruiting?
Yes, NCT06183645 is actively recruiting participants. Contact the research team at laurie.medard@citadelle.be for enrollment information.
Where is the NCT06183645 trial being conducted?
This trial is being conducted at Liège, Belgium.
Who is sponsoring the NCT06183645 clinical trial?
NCT06183645 is sponsored by Centre Hospitalier Universitaire de Liege. The principal investigator is Margaux Poleur, Dr at CHR Citadelle. The trial plans to enroll 40 participants.